Back to search
FDAFDA · Food and drugs·Recall number D-0288-2021

Fludeoxyglucose F 18 Injection, 20-300 mCi/mL at End of Synthesis (EOS) Solution, 50 mL glass vial, Rx only, Manufactured by Massachusetts General Hospital PET Center, Boston, MA NDC 76318-334-50

Published March 3, 2021 · Recall initiated: February 17, 2021

Summary

FDA records drug Class II recall D-0288-2021, published March 3, 2021 and initiated February 17, 2021. Recalling firm: The General Hospital Corporation; Status: Terminated; Reported quantity: 50 mL vial; Lot: Lot # P01-021721, exp 02/17/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Telephone

Get an email if FLUDEOXYGLUCOSE F 18 has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
FLUDEOXYGLUCOSE F 18
Manufacturer
The General Hospital Corporation
Distributor
Product was distributed to one direct account.
Lot
Lot # P01-021721, exp 02/17/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Fludeoxyglucose F 18 Injection, 20-300 mCi/mL at End of Synthesis (EOS) Solution, 50 mL glass vial, Rx only, Manufactured by Massachusetts General Hospital PET Center, Boston, MA NDC 76318-334-50 recalled?

Yes. FDA published recall D-0288-2021 on March 3, 2021. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Telephone

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: FLUDEOXYGLUCOSE F 18.